VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LGNDLigand Pharmaceuticals Incorporated
$303.59$6.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksLGNDFinancials

Ligand Pharmaceuticals Incorporated (LGND) Financials

30Y historyFree accessUpdated daily

Revenue growth remains highly erratic due to the lumpiness of milestone payments, with operating margins swinging from a negative 79.9% in 2025Q1 to a positive 47.6% in 2025Q3.

LGND Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue274.48M268.09M167.13M131.31M196.25M241.54M163.56M120.28M251.45M141.1M108.97M71.91M64.54M48.97M31.39M30.04M23.54M38.94M27.32M12.89M140.96M176.61M163.51M141.14M96.64M76.34M48.11M40.9M17.7M51.7M36.8M
Revenue Growth %51.24%60.4%27.28%-33.09%-18.75%47.68%35.98%-52.17%78.21%29.48%51.53%11.43%31.78%56.03%4.5%27.61%-39.55%42.56%111.84%-90.85%-20.18%8.01%15.85%46.05%26.59%58.68%17.63%131.07%-65.76%40.49%50.2%
Cost of Goods Sold3.81M6.59M11.07M35.05M52.83M62.18M30.42M11.35M6.34M5.37M5.57M5.81M9.14M5.73M3.6M4.91M015.23M0022.64M39.85M39.8M31.62M20.31M13.95M1.62M3.1M-7.7M-9.8M-9.4M
COGS % of Revenue-2.46%6.63%26.69%26.92%25.74%18.6%9.43%2.52%3.8%5.11%8.07%14.16%11.71%11.47%16.34%-39.12%--16.06%22.56%24.34%22.4%21.01%18.27%3.36%7.58%-43.5%-18.96%-25.54%
Gross Profit270.66M261.5M156.06M96.27M143.42M179.37M133.14M108.94M245.12M135.74M103.4M66.11M55.4M43.24M27.79M25.13M23.54M23.7M27.32M12.89M118.32M136.76M123.71M109.52M76.33M62.39M46.49M37.8M25.4M61.5M46.2M
Gross Margin %98.61%97.54%93.37%73.31%73.08%74.26%81.4%90.57%97.48%96.2%94.89%91.93%85.84%88.29%88.53%83.66%100%60.88%100%100%83.94%77.44%75.66%77.6%78.99%81.73%96.64%92.42%143.5%118.96%125.54%
Gross Profit Growth %-67.56%62.11%-32.88%-20.04%34.72%22.22%-55.56%80.58%31.27%56.42%19.32%28.12%55.62%10.58%6.75%-0.7%-13.22%111.84%-89.1%-13.49%10.55%12.95%43.48%22.34%34.2%22.99%48.82%-58.7%33.12%63.83%
Operating Expenses169.88M214.3M178.66M84.32M140.38M75.52M95.64M-698.14M81.39M67.66M58.48M37.76M34.69M27.26M26.9M25.27M51.79M70.32M52.59M73.07M287.09M163.23M161.08M128.7M100.48M85.53M92.37M94.1M95M92.3M79.1M
OpEx % of Revenue-79.94%106.9%64.21%71.53%31.26%58.48%-580.42%32.37%47.95%53.67%52.5%53.75%55.66%85.7%84.12%220.03%180.58%192.54%566.69%203.67%92.43%98.51%91.19%103.98%112.04%192.01%230.07%536.72%178.53%214.95%
Selling, General & Admin94.48M92.45M78.65M52.79M70.06M46.79M60.01M41.88M37.73M28.65M26.62M24.38M22.57M17.98M16.11M14.98M29.72M15.21M23.79M30.41M248.28M107.16M95.88M61.02M41.68M34.43M34.11M27.3M16.6M10.1M10.2M
SG&A % of Revenue-34.48%47.06%40.2%35.7%19.37%36.69%34.82%15.01%20.31%24.43%33.9%34.97%36.72%51.32%49.86%126.28%39.06%87.08%235.85%176.14%60.68%58.63%43.23%43.13%45.1%70.91%66.75%93.79%19.54%27.72%
Research & Development33.24M81.18M21.43M24.54M36.08M32.1M40.5M55.91M27.86M26.89M21.22M13.38M12.12M9.27M10.79M10.29M22.07M39.87M30.77M44.62M41.93M56.08M65.2M67.68M58.81M51.1M51.29M59.4M70.7M72.4M59.5M
R&D % of Revenue-30.28%12.82%18.69%18.39%13.29%24.76%46.48%11.08%19.05%19.47%18.61%18.78%18.94%34.38%34.26%93.75%102.39%112.65%346.08%29.74%31.75%39.88%47.95%60.85%66.94%106.6%145.23%399.44%140.04%161.68%
Other Operating Expenses2M40.67M78.59M7M34.24M-3.38M-4.87M-795.93M15.79M12.12M10.64M0000000-1.96M-1.96M-3.12M000006.97M7.4M7.7M9.8M9.4M
Operating Income100.78M47.2M-22.61M11.94M3.04M103.85M37.5M807.08M163.73M68.08M43.88M27.33M19.63M14.94M574K-698K-29.3M-9.97M-97.28M-60.17M-168.77M-26.47M-37.37M-19.18M-24.15M-23.14M-45.88M-56.3M-69.6M-30.8M-32.9M
Operating Margin %36.72%17.61%-13.53%9.09%1.55%42.99%22.93%670.99%65.11%48.25%40.27%38%30.41%30.51%1.83%-2.32%-124.5%-25.6%-356.13%-466.69%-119.73%-14.99%-22.86%-13.59%-24.99%-30.31%-95.37%-137.65%-393.22%-59.57%-89.4%
Operating Income Growth %-308.79%-289.3%293.22%-97.08%176.94%-95.35%392.94%140.51%55.12%60.58%39.25%31.34%2503.31%182.23%97.62%-194.01%89.75%-61.66%64.34%-537.57%29.17%-94.86%20.59%-4.38%49.57%18.5%19.11%-125.97%6.38%-32.13%
EBITDA127.02M80.97M12.63M48.46M46.43M154.8M65.47M850.81M180.42M80.6M55.17M29.96M22.28M17.61M3.3M2.09M-27.09M-6.83M-96.22M-57.56M-152.55M-7.76M-22.1M-4.9M-13.68M-16.56M-38.91M-48.9M-61.9M-21M-23.5M
EBITDA Margin %46.28%30.2%7.56%36.91%23.66%64.09%40.03%707.34%71.75%57.12%50.63%41.66%34.53%35.95%10.52%6.96%-115.1%-17.55%-352.28%-446.41%-108.22%-4.4%-13.51%-3.47%-14.15%-21.7%-80.88%-119.56%-349.72%-40.62%-63.86%
EBITDA Growth %578.15%540.97%-73.93%4.38%-70.01%136.45%-92.31%371.57%123.86%46.07%84.19%34.43%26.56%433.35%57.79%107.72%-296.49%92.9%-67.17%62.27%-1864.88%64.86%-351.12%64.19%17.42%57.43%20.43%21%-194.76%10.64%-10.85%
D&A (Non-Cash Add-back)26.24M33.77M35.24M36.52M43.39M50.95M27.97M43.73M16.69M12.52M11.29M2.63M2.66M2.66M2.73M2.79M2.21M3.13M1.05M2.62M16.22M18.71M15.28M14.28M10.47M6.57M6.97M7.4M7.7M9.8M9.4M
EBIT227.66M158.96M5.55M64.32M37.81M91.82M28.71M832.38M221.61M68.63M20.8M27.33M20.71M15.98M1.22M254K-15.35M-9.6M-97.31M-52.72M-78.08M-43.63M-15.38M-74.02M-43.85M-23.14M-45.88M-61.29M-69.6M-30.8M-32.9M
Net Interest Income12.95M8.94M5.02M7.05M247K-18.73M-19.34M-7.32M-34.28M-11.4M-12.18M-11.8M-4.86M-2.08M-2.92M-2.3M382K316K1.96M7.92M00000000000
Interest Income14.1M8.94M8.05M7.71M2.05M886K8.08M28.43M14M00000381K31K440K586K2.16M8.65M00000000000
Interest Expense1.15M03.04M656K1.8M19.62M27.41M35.74M48.28M11.4M12.18M11.8M4.86M2.08M3.31M2.51M58K270K202K735K00000000000
Other Income/Expense84.1M111.76M25.12M51.72M32.97M-31.65M-36.21M-10.44M9.6M-10.85M-35.92M8M-8.32M-5.74M-4.44M-2.86M13.9M95K-239K6.72M-96.19M-9.87M-7.54M-20.39M-8.36M-8.36M-825K-707K-43M-61.3M3.7M
Pretax Income184.88M158.96M2.52M63.66M36.01M72.2M1.29M796.64M173.33M57.23M7.96M35.33M11.3M9.21M-3.87M-2.93M-15.4M-9.87M-97.52M-53.46M-174.27M36.34M-44.91M-37.46M-32.6M-31.5M-46.71M-62M-112.6M-92.1M-29.2M
Pretax Margin %67.36%59.29%1.51%48.48%18.35%29.89%0.79%662.31%68.93%40.56%7.3%49.13%17.51%18.8%-12.31%-9.75%-65.44%-25.35%-357%-414.58%-123.63%20.58%-27.46%-26.54%-33.73%-41.26%-97.08%-151.59%-636.16%-178.14%-79.35%
Income Tax31.32M34.51M6.55M9.84M41.23M-4.15M-5.31M167.34M30.01M44.67M10.33M-219.6M410K374K-1.19M-13.1M-2.62M-7.92M-55K-18.7M-38.41M59K233K18.28M8.45M19.86M26.49M18.4M48.3M69.4M4.4M
Effective Tax Rate %16.94%21.71%260.13%15.46%114.49%-5.74%-410.68%21.01%17.31%78.06%129.74%-621.57%3.63%4.06%30.82%447.2%16.99%80.27%0.06%34.98%22.04%0.16%-0.52%-48.81%-25.91%-63.04%-56.72%-29.68%-42.9%-75.35%-15.07%
Net Income153.56M124.45M-4.03M52.15M-33.36M57.14M-2.98M629.3M143.32M12.56M-1.64M257.31M12.02M11.42M-527K10.18M-12.52M-1.95M-98.11M281.69M-31.74M-36.4M-45.14M-37.46M-32.6M-42.99M-72.38M-74.7M-117.9M-100.2M-37.3M
Net Margin %55.95%46.42%-2.41%39.72%-17%23.66%-1.82%523.19%57%8.9%-1.5%357.8%18.63%23.32%-1.68%33.88%-53.17%-5%-359.19%2184.64%-22.52%-20.61%-27.61%-26.54%-33.73%-56.32%-150.44%-182.64%-666.1%-193.81%-101.36%
Net Income Growth %215.79%3186.63%-107.73%256.33%-158.39%2014.17%-100.47%339.09%1041.45%867.48%-100.64%2039.93%5.28%2267.17%-105.18%181.31%-542.45%98.01%-134.83%987.4%12.79%19.37%-20.5%-14.93%24.19%40.59%3.11%36.64%-17.66%-168.63%41.9%
Net Income (Continuing)153.56M124.45M-4.03M53.82M-5.22M76.35M6.6M629.3M143.32M12.56M-2.37M227.44M10.89M8.83M-2.67M9.71M-12.79M-8.34M-97.46M-34.76M-56.59M-36.03M-45.14M-94.47M-52.26M-42.99M-59.28M-74.72M-117.9M-100.2M-37.3M
Discontinued Operations000-1.67M-28.14M-19.21M-9.58M000731K002.59M00000000000000000
Minority Interest000000000000-1.91M000000000000000000
EPS (Diluted)7.726.13-0.222.94-1.983.34-0.1831.855.960.53-0.0812.120.560.55-0.030.52-0.64-0.10-6.1617.22-2.36-2.95-3.68-3.18-2.83-4.34-7.80-9.51-17.51-18.15-7.78
EPS Growth %203.51%2886.36%-107.48%248.48%-159.28%1955.56%-100.57%434.4%1024.53%775.16%-100.65%2064.29%1.82%2175.47%-105.1%181.25%-540%98.38%-135.77%829.66%20%19.84%-15.72%-12.37%34.79%44.36%17.98%45.69%3.53%-133.29%54.74%
EPS (Basic)-6.44-0.223.02-1.983.46-0.1833.135.960.60-0.0813.000.590.56-0.030.52-0.64-0.10-6.1617.22-2.36-2.95-3.68-3.18-2.83-4.34-7.80-9.51-17.51-18.15-7.78
Diluted Shares Outstanding19.88M20.29M18.29M17.76M16.87M17.25M16.18M19.76M24.07M23.48M20.83M21.23M21.43M20.75M19.85M19.71M19.61M18.86M15.92M16.35M13.44M12.34M12.28M11.78M11.52M9.9M9.28M7.86M6.73M5.52M4.8M
Basic Shares Outstanding19.88M19.34M18.29M17.3M16.87M16.63M16.18M19M24.05M21.03M20.83M19.79M20.42M20.31M19.1M19.66M19.61M18.86M15.92M16.35M13.44M12.34M12.28M11.78M11.52M9.9M9.28M7.86M6.73M5.52M4.8M
Dividend Payout Ratio-------------------89.72%-----------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

High Revenue Concentration Volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Driven By Volatility

As reported in recent financial filings, Ligand's revenue growth has exhibited extreme quarterly variance, peaking at 122.8% in 2025Q3 before moderating to 14.1% in 2026Q1, reflecting the inherent lumpiness of milestone payments and the unpredictable nature of Captisol material sales across the company's diverse partner pipeline.

The top-line trajectory appears heavily influenced by transactional milestone events rather than consistent organic royalty expansion. Investors should monitor whether the underlying royalty base can sustain growth as the contribution from specific high-visibility assets like Veklury potentially normalizes over the coming fiscal periods.

Structural Gross Margin Resilience Tested

Based on reported figures, Ligand maintains a structurally high gross margin profile, though quarterly fluctuations—ranging from 64.3% to 143.6%—suggest that accounting adjustments and the timing of material cost recognition significantly distort the core profitability of the royalty-heavy business model on a period-to-period basis.

While the 97.54% average gross margin indicates a highly efficient intellectual property-based model, the volatility in reported COGS warrants caution. This suggests that the company's reported margins may not always reflect the true cash-generative capacity of its royalty streams, necessitating a focus on normalized profitability metrics.

Operating Leverage Constrained By Overhead

According to recent SEC filings, Ligand's operating income has struggled to scale consistently with gross profit, as evidenced by an operating margin that swung from -79.9% in 2025Q1 to 47.6% in 2025Q3, highlighting the impact of fixed SG&A costs on a relatively small revenue base.

The inability to maintain consistent operating leverage suggests that the company's current cost structure may be optimized for future deal-making rather than immediate profitability. Investors should investigate whether the current SG&A burden is a permanent feature of the platform or if it can be rationalized as the portfolio matures.

Earnings Quality Obscured By Items

As indicated in financial statements, Ligand's net income is frequently impacted by non-operating items and significant stock-based compensation, which reached $14.7M in 2025Q3, complicating the assessment of true recurring earnings power and creating a disconnect between GAAP net income and operational cash flow performance.

The wide variance in net margins, which have fluctuated between -125% and 101.6%, suggests that GAAP earnings are an unreliable indicator of the company's fundamental health. Analysts should prioritize cash-based metrics to strip away the noise created by intangible asset amortization and the lumpy recognition of milestone-related income.

Sustainability Of Royalty Base Challenged

Based on reported figures, the heavy reliance on a concentrated set of commercialized assets creates a significant risk profile, as the potential for patent cliffs or competitive entry could rapidly erode the royalty streams that currently underpin the company's valuation and long-term financial stability.

Short-term growth spikes may mask a long-term degradation in the quality of the royalty portfolio if new acquisitions fail to replace the revenue lost from aging assets. The market may be overestimating the durability of these cash flows, particularly if the pipeline of new partnered programs fails to reach commercialization at the expected rate.

LGND — Frequently Asked Questions

Quick answers to the most common questions about buying LGND stock.

What was Ligand Pharmaceuticals Incorporated's (LGND) revenue in 2025?

For fiscal year 2025, Ligand Pharmaceuticals Incorporated (LGND) reported total revenue of $268.1M. This represents a 628.5% increase compared to $36.8M in 1996.

Is Ligand Pharmaceuticals Incorporated (LGND) profitable?

Ligand Pharmaceuticals Incorporated (LGND) is profitable, generating $124.5M in net income for the fiscal year ending 2025 with a net profit margin of 46.4%.

What is Ligand Pharmaceuticals Incorporated's operating profit margin?

Ligand Pharmaceuticals Incorporated (LGND) reported an operating income of $47.2M, resulting in an operating profit margin of 17.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Ligand Pharmaceuticals Incorporated's gross profit and gross margin?

Ligand Pharmaceuticals Incorporated (LGND) generated $261.5M in gross profit for the year, representing a gross profit margin of 97.5%. This demonstrates the company's core pricing power and production efficiency.